Board of Directors

Born 1962. Øvlesen has experience in business development and has been involved in more than 20 successful start-ups in medtech, biotech, and IT, including CLC Bio, Cetrea and Monsenso. Øvlesen is Co-founder, board member and CEO at SynAct Pharma AB (publ), and has previously been CEO at ChemoMetec A/S and PNN Medical A/S. Previous experience also includes founding TXP Pharma, and holding executive positions as CFO and Vice President of business development at Action Pharma A/S, whose lead candidate was sold to AbbVie for 110 MUSD. Øvlesen is currently chairman in HG Energy Group A/S, Cercare Medical A/S, Go-Pen A/S, and Neurescue ApS, and is a board member in Perfusion Tech Aps, and ResoTher Pharma Aps. Øvlesen has an MBA with a focus on leadership and finance from the University of Hartford, US. He was a Board member of Cereno Scientific from 2023-2025.

Considered dependent of the company, but independent of its management and major shareholders.

Shareholding: 85,234 Class B Shares and 1,000,000 warrants.

Born 1987. Moi Brajanovic has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. He is currently Managing Director at Advisense, a leading European company within governance, risk and compliance. Moi holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg.

Considered independent of the company, its management and major shareholders.

Shareholding: 407,000 Class B shares

Born 1953. Dr. Gunnar Olsson is an MD, PhD in Medical Sciences at the Karolinska Institute. Dr. Gunnar Olsson is an MD, PhD in Medical Sciences at the Karolinska Institute. He was previously Adjunct Professor at the Karolinska Institute and has extensive experience from leading R&D positions in the pharmaceutical industry. He has over 20 years of experience in different Global R&D management positions at AstraZeneca and contributed to more than a dozen successful global product registrations for medicines in cardiovascular, vascular and gastrointestinal indications. Dr. Gunnar Olsson has been on the board of ESC, that awarded him the ESC President Award in recognition of his outstanding lifetime achievements, in 2023. He was a board member in Cereno Scientific between 2016-2018 and has been a member of the Scientific Advisory Board since this was established in 2019. Dr. Gunnar Olsson has been a senior advisor to the executive management team since 2018. Olsson is a Board member of IRLAB Therapeutics AB and Amplifier Tx AB. He is Vice Chair for the Swedish Heart Lung Foundation and Bundy Academy, Lund University.

Considered independent of the company, its management and major shareholders.

Shareholding: 5,000 Class B shares and 600,000 warrants.

Born 1951. Dr. Anders Svensson is a licensed physician, medical doctor, and lecturer with over 20 years of experience in academic medicine; his scientific focus is cardiovascular diseases. He has extensive experience in international pharmaceutical development after almost 20 years in leading positions within the global pharmaceutical industry such as F. Hoffmann-LaRoche where he was responsible for the global clinical development of diabetes and cardiovascular. Prior to that he was working as Vice President and responsible for the clinical development of cardiovascular and later gastrointestinal drugs at AstraZeneca. Anders Svensson has almost 100 publications to his name. Anders Svensson holds a MD, Ph.D. from the University of Gothenburg. He is founder of C Anders Svensson Consulting.

Considered independent of the company, its management and major shareholders.

Shareholding: 488,200 B shares and 1,100,000 warrants

Sten R. Sörensen has been the CEO of Cereno Scientific since 2015 and has extensive experience from the pharma, biotech, and finance industries. Prior to Cereno Scientific, he held senior positions in major pharma including Head of International Marketing Operations for the 10 BSEK pharma portfolio at Monsanto and Global Marketing Director for the 4 BSEK portfolio of Secondary Prevention Products, Cardiovasculars at AstraZeneca. At Monsanto and AstraZeneca, he initiated two groundbreaking preventive survival studies in heart failure, RALES and MERIT-HF, both establishing a paradigm shift for mineralocorticoid receptor (MR) antagonism and beta-blocker drug therapies in heart failure, significantly improving quality of life and life expectancy. He was also a Board member of Cereno Scientific between 2014-2016. Sten holds a bachelor’s degree in chemistry from Lund University. He is the Chairman of SARomics Biostructure and board member of SynAct Pharma.

Considered dependent of the company and its management, but independent of major shareholders.

Shareholding: 1,995,179 Class B shares and 5,000,000 warrants